The new test promises to be “minimally invasive” and can help doctors identify symptoms of Alzheimer’s disease earlier.

The FDA has cleared PrecivityAD2, a single blood test designed to help health care professionals rule in or rule out an Alzheimer’s disease diagnosis, according to a press release…

PrecivityAD2 is the first blood-based biomarker for people as young as 40 with cognitive symptoms